<DOC>
	<DOCNO>NCT00532558</DOCNO>
	<brief_summary>The purpose study determine reduction LDL-cholesterol level treatment 50 mg per day lapaquistat acetate daily ( QD ) .</brief_summary>
	<brief_title>Efficacy Lapaquistat Acetate Blood Cholesterol Levels Treating Subjects With Hypercholesterolemia</brief_title>
	<detailed_description>This study conduct determine potential lapaquistat acetate 50 mg per day lower LDL-C level compare placebo . This study also conduct evaluate safety tolerability lapaquistat acetate 50 mg period 12 week . An optional , 48-week , open-label extension follow 12 week , double-blind treatment period evaluate long-term safety tolerability lapaquistat acetate 50 mg/day .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Females childbearing potential sexually active must agree use adequate contraception screen throughout duration study 30 day follow last dose . Prior Randomization , participant mean low density lipoprotein cholesterol level great equal 130 mg/dL less equal 190 mg/dL 2 consecutive sample . Prior Randomization , subject mean triglyceride level great equal 400 mg/dL 2 consecutive sample . Is willing able comply recommend , standardize diet . Has nine aminotransferase aspartate aminotransferase level great 1.5 time upper limit normal , identified screening . Has serum creatinine great 133 mmol/L , identify screening . Has creatine kinase great 3 time upper limit normal , identified screening . Has active liver disease jaundice . Has take fibrates within 42 day Visit 1 lipidlowering therapy least 30 day prior Screening . Has previous history cancer remission le 5 year prior first dose study medication . Has endocrine disorder , Cushing 's syndrome , hyperthyroidism , inappropriately treated hypothyroidism affect lipid metabolism . Has history myocardial infarction , angina pectoris , unstable angina , transient ischemic attack , cerebrovascular accident , peripheral vascular disease , abdominal aortic aneurysm , coronary angioplasty , coronary peripheral arterial surgery , multiple risk factor confer 10year risk cardiovascular heart disease great 20 % base Framingham risk scoring . Has positive hepatitis B surface antigen hepatitis C virus antibody test , determine medical history . Has positive human immunodeficiency virus status take antiretroviral medication , determine medical history and/or subject 's verbal report . Has receive investigational medication 30 day prior screen , ( drug long halflife , within period le 5 time drug 's halflife ) participate investigational study . Has receive lapaquistat acetate previous clinical study therapeutic agent . Has history presence clinically significant food allergy would prevent adherence specialize diet . Has know heterozygous homozygous familial hypercholesterolemia know type III hyperlipoproteinemia ( familial dysbetalipoproteinemia ) . Has fibromyalgia , myopathy , rhabdomyolysis , unexplained muscle pain . Has uncontrolled hypertension Has inflammatory bowel disease malabsorption syndrome , gastric bypass surgical procedure weight loss . Has history drug abuse history high alcohol intake within previous 2 year . Has type 1 2 diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>